BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 33932725)

  • 1. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
    Mout L; van Dessel LF; Kraan J; de Jong AC; Neves RPL; Erkens-Schulze S; Beaufort CM; Sieuwerts AM; van Riet J; Woo TLC; de Wit R; Sleijfer S; Hamberg P; Sandberg Y; Te Boekhorst PAW; van de Werken HJG; Martens JWM; Stoecklein NH; van Weerden WM; Lolkema MP
    Eur J Cancer; 2021 Jun; 150():179-189. PubMed ID: 33932725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.
    Tamminga M; Andree KC; van den Bos H; Hiltermann TJN; Mentink A; Spierings DCJ; Lansdorp P; Timens W; Schuuring E; Terstappen LWMM; Groen HJM
    Br J Cancer; 2022 Feb; 126(3):409-418. PubMed ID: 34848855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.
    Franken A; Driemel C; Behrens B; Meier-Stiegen F; Endris V; Stenzinger A; Niederacher D; Fischer JC; Stoecklein NH; Ruckhaeberle E; Fehm T; Neubauer H
    Clin Chem; 2019 Apr; 65(4):549-558. PubMed ID: 30737205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.
    Rieckmann LM; Spohn M; Ruff L; Agorku D; Becker L; Borchers A; Krause J; O'Reilly R; Hille J; Velthaus-Rusik JL; Beumer N; Günther A; Willnow L; Imbusch CD; Iglauer P; Simon R; Franzenburg S; Winter H; Thomas M; Bokemeyer C; Gagliani N; Krebs CF; Sprick M; Hardt O; Riethdorf S; Trumpp A; Stoecklein NH; Peine S; Rosenstiel P; Pantel K; Loges S; Janning M
    Mol Cancer; 2024 May; 23(1):93. PubMed ID: 38720314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting.
    Fehm TN; Meier-Stiegen F; Driemel C; Jäger B; Reinhardt F; Naskou J; Franken A; Neubauer H; Neves RPL; van Dalum G; Ruckhäberle E; Niederacher D; Rox JM; Fischer JC; Stoecklein NH
    Cytometry A; 2018 Dec; 93(12):1213-1219. PubMed ID: 30551262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).
    Andree KC; Mentink A; Zeune LL; Terstappen LWMM; Stoecklein NH; Neves RP; Driemel C; Lampignano R; Yang L; Neubauer H; Fehm T; Fischer JC; Rossi E; Manicone M; Basso U; Marson P; Zamarchi R; Loriot Y; Lapierre V; Faugeroux V; Oulhen M; Farace F; Fowler G; Sousa Fontes M; Ebbs B; Lambros M; Crespo M; Flohr P; de Bono JS
    Int J Cancer; 2018 Nov; 143(10):2584-2591. PubMed ID: 30006930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis.
    Stoecklein NH; Fluegen G; Guglielmi R; Neves RPL; Hackert T; Birgin E; Cieslik SA; Sudarsanam M; Driemel C; van Dalum G; Franken A; Niederacher D; Neubauer H; Fehm T; Rox JM; Böhme P; Häberle L; Göring W; Esposito I; Topp SA; Coumans FAW; Weitz J; Knoefel WT; Fischer JC; Bork U; Rahbari NN
    Mol Cancer; 2023 Nov; 22(1):181. PubMed ID: 37957606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer.
    Dong L; Zhang Z; Smith K; Kuczler MD; Reyes D; Amend SR; Cho YK; Xue W; Pienta KJ
    BJU Int; 2020 Jul; 126(1):191-201. PubMed ID: 32115854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients.
    Fischer JC; Niederacher D; Topp SA; Honisch E; Schumacher S; Schmitz N; Zacarias Föhrding L; Vay C; Hoffmann I; Kasprowicz NS; Hepp PG; Mohrmann S; Nitz U; Stresemann A; Krahn T; Henze T; Griebsch E; Raba K; Rox JM; Wenzel F; Sproll C; Janni W; Fehm T; Klein CA; Knoefel WT; Stoecklein NH
    Proc Natl Acad Sci U S A; 2013 Oct; 110(41):16580-5. PubMed ID: 24065821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved enrichment of circulating tumor cells from diagnostic leukapheresis product.
    Stevens M; Mentink A; Nanou A; Coumans FAW; Isebia KT; Kraan J; Hamberg P; Martens JWM; Terstappen LWMM
    Cytometry A; 2023 Nov; 103(11):881-888. PubMed ID: 37461156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
    Jiang R; Lu YT; Ho H; Li B; Chen JF; Lin M; Li F; Wu K; Wu H; Lichterman J; Wan H; Lu CL; OuYang W; Ni M; Wang L; Li G; Lee T; Zhang X; Yang J; Rettig M; Chung LW; Yang H; Li KC; Hou Y; Tseng HR; Hou S; Xu X; Wang J; Posadas EM
    Oncotarget; 2015 Dec; 6(42):44781-93. PubMed ID: 26575023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analogous detection of circulating tumor cells using the AccuCyte
    van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
    Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A Large Number of Circulating Tumor Cells(CTCs)Can Be Isolated from Samples Obtained by Using Leukapheresis Procedures].
    Soya R; Taguchi J; Nagakawa Y; Takahashi O; Sandoh N; Hosokawa Y; Kasuya K; Umeda N; Okamoto M; Tsujitani S; Tsuchida A
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1069-72. PubMed ID: 26469161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of rare circulating tumour cells in cancer patients by microchip technology.
    Nagrath S; Sequist LV; Maheswaran S; Bell DW; Irimia D; Ulkus L; Smith MR; Kwak EL; Digumarthy S; Muzikansky A; Ryan P; Balis UJ; Tompkins RG; Haber DA; Toner M
    Nature; 2007 Dec; 450(7173):1235-9. PubMed ID: 18097410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance.
    Reinhardt F; Franken A; Meier-Stiegen F; Driemel C; Stoecklein NH; Fischer JC; Niederacher D; Ruckhaeberle E; Fehm T; Neubauer H
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technical validation of a new microfluidic device for enrichment of CTCs from large volumes of blood by using buffy coats to mimic diagnostic leukapheresis products.
    Guglielmi R; Lai Z; Raba K; van Dalum G; Wu J; Behrens B; Bhagat AAS; Knoefel WT; Neves RPL; Stoecklein NH
    Sci Rep; 2020 Nov; 10(1):20312. PubMed ID: 33219265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow-based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product.
    Stevens M; Mentink A; Coumans FAW; Dathathri E; Isebia KT; Kraan J; de Wit R; Martens JWM; Terstappen LWMM
    Mol Oncol; 2023 Dec; ():. PubMed ID: 38073130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma.
    Wu YH; Hung YP; Chiu NC; Lee RC; Li CP; Chao Y; Shyr YM; Wang SE; Chen SC; Lin SH; Chen YH; Kang YM; Hsu SM; Yen SH; Wu JY; Lee KD; Tseng HE; Tsai JR; Tang JH; Chiou JF; Burnouf T; Chen YJ; Wang PY; Lu LS
    Eur J Cancer; 2022 May; 166():208-218. PubMed ID: 35306319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.